Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 34

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 34
---
 compensation data from our compensation peer group as one of several factors that informs our judgment of appropriate parameters for compensation levels. We do not strictly benchmark compensation to a specific percentile of our compensation peer group, nor do we apply a formula or assign relative weightings to specific compensation elements. We believe that over-reliance on benchmarking can result in compensation that is unrelated to the value delivered by our Named Executive Officers because it does not take into account the specific performance of the Named Executive Officers, the relative size, growth, and performance of the Company, or any unique circumstances or strategic considerations of the Company. In evaluating and determining Named Executive Officer compensation, the Compensation Committee also considers the results of our most recent Say-on-Pay vote and other feedback from our shareholders.

Role of the Compensation Committee

Pursuant to its charter, the Compensation Committee assists the Board in its oversight of the performance and compensation of the Named Executive Officers. In making executive compensation decisions, the Compensation Committee seeks the assistance of its independent compensation consultant, Compensia, Inc. (“Compensia”), as well as our CEO and our management team (except with respect to their own compensation). The Compensation Committee reviews the cash and equity compensation of our Named Executive Officers to properly incentivize and reward them for their performance. The role of the Compensation Committee includes:

Reviewing and approving individual and corporate goals and objectives relevant to Named Executive Officer compensation and evaluating the performance of each Named Executive Officer in light of those goals and objectives;

Reviewing and approving, or recommending for approval by the independent directors (as directed by the Board), Named Executive Officer compensation, including salary, bonus and incentive compensation, deferred compensation, perquisites, equity compensation, benefits provided upon retirement, severance or other compensation upon termination of employment and any other forms of Named Executive Officer compensation; and

Annually reviewing and approving, or recommending for approval by the independent directors (as

25

directed by the Board), the CEO’s compensation based on the Compensation Committee’s evaluation of the CEO’s performance. Effective in fiscal 2025, the Compensation Committee will annually recommend CEO compensation changes to the full Board for approval. Role of the Compensation Consultant The Compensation Committee has the authority, in its sole discretion, to engage any compensation consultant to assist in the evaluation of Named Executive Officer compensation, and has the authority to approve the consultant’s fees. Prior to retaining any such consultant, the Compensation Committee conducts an analysis of such consultant’s independence pursuant to the Nasdaq rules. The Compensation Committee may also commission various compensation studies it deems